APOGEE THERAPEUTICS I

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

12 May 2025 03:05:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

12 May 2025 03:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

01 May 2025 05:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

03 Mar 2025 03:05:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

03 Mar 2025 03:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

28 Feb 2025 13:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

25 Feb 2025 04:30:52 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

03 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

29 Jan 2025 04:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

10 Dec 2024 04:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

02 Dec 2024 03:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces Agenda for Virtual R&D Day

29 Nov 2024 10:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

18 Nov 2024 04:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

12 Nov 2024 04:00:01 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

04 Nov 2024 04:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

24 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

16 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

12 Sep 2024 04:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

09 Sep 2024 04:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

19 Aug 2024 04:00:00 By Nasdaq GlobeNewswire